Jazz Pharmaceuticals PLC represents values of innovation, integrity, and patient-centered healthcare. With a corporate philosophy focused on improving the lives of patients, Jazz Pharmaceuticals operates with a commitment to discovering, developing, and delivering meaningful solutions in the field of neuroscience and oncology. The company strives to address unmet medical needs and enhance patient outcomes through research and development of novel therapies. Jazz Pharmaceuticals PLC emphasizes collaboration, ethical practices, and a drive for excellence in every aspect of its operations. Its dedication to these values has made it a recognized leader in the pharmaceutical industry.

Jazz Pharmaceuticals PLC is primarily present in various countries and regions around the world. The company operates in the United States, Europe, and other international markets. With its headquarters in Dublin, Ireland, Jazz Pharmaceuticals has a significant presence in North America, including the United States and Canada. Additionally, the company has expanded its operations in Europe, serving countries such as Germany, France, Italy, Spain, and the United Kingdom, among others. Jazz Pharmaceuticals PLC continues to focus on global growth and has established partnerships and collaborations in different regions to enhance its presence and reach in the pharmaceutical market.

Jazz Pharmaceuticals PLC has achieved several significant milestones throughout its history. One notable achievement includes the successful development and FDA approval of their flagship product, Xyrem, which is used to treat narcolepsy. Another milestone for the company was the acquisition of Celator Pharmaceuticals, which expanded their oncology portfolio. Additionally, Jazz Pharmaceuticals PLC received FDA approval for Defitelio, an innovative treatment for a rare and life-threatening post-transplant condition known as hepatic veno-occlusive disease. These milestones demonstrate Jazz Pharmaceuticals PLC's commitment to developing innovative therapies and expanding their presence in the pharmaceutical industry.

Jazz Pharmaceuticals PLC is a renowned biopharmaceutical company with a rich history and background. Established in 2003, Jazz Pharmaceuticals has quickly emerged as a global leader in developing and commercializing innovative medicines to address unmet medical needs. The company focuses on complex diseases and conditions, primarily in the areas of sleep and hematology/oncology. Jazz Pharmaceuticals PLC has built a strong reputation for its commitment to scientific excellence, patient-centered approaches, and fostering collaborations worldwide. With a diverse portfolio of breakthrough treatments, the company continues to strive for advancements in patient care and improve the quality of life for individuals around the globe.

The main competitors of Jazz Pharmaceuticals PLC in the market include Biogen Inc., Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.

Jazz Pharmaceuticals PLC is primarily active in the pharmaceutical industry.

Jazz Pharmaceuticals PLC operates under a business model focused on the development and commercialization of innovative specialty pharmaceuticals. The company specializes in the identification and acquisition of highly-differentiated products to address unmet medical needs. Jazz Pharmaceuticals PLC leverages its expertise in medical research, regulatory affairs, and commercialization to bring these products to market and improve patient outcomes. By prioritizing research and development, strategic partnerships, and targeted marketing efforts, the company aims to provide effective and safe treatments to patients in need. Jazz Pharmaceuticals PLC is committed to advancing healthcare and remains dedicated to its mission of improving and prolonging patients' lives through innovative pharmaceutical solutions.

Jazz Pharmaceuticals KGV ir 6,08.

Jazz Pharmaceuticals KUV ir 1,76.

AlleAktien kvalitātes vērtējums Jazz Pharmaceuticals ir 5/10.

gaidāmā Jazz Pharmaceuticals apgrozījums ir 4,13 miljardi USD.

gaidāmā Jazz Pharmaceuticals peļņa ir 1,19 miljardi USD.

Jazz Pharmaceuticals PLC is a biopharmaceutical company based in Dublin, Ireland. The company specializes in the development and marketing of drugs for the treatment of rare and complex diseases. The business strategy of Jazz Pharmaceuticals is based on a product portfolio that focuses on four core areas: sleep disorders, oncology, neuropathic pain, and hemophilia. Each area is characterized by a combination of internal research and development programs, as well as acquisitions and licensing agreements. The sleep disorders area includes Jazz Pharmaceuticals' flagship product, Xyrem. The product is an oral solution used to treat cataplexy in adult patients with narcolepsy. Xyrem is the only drug approved by the US Food and Drug Administration (FDA) to treat the symptoms of narcolepsy. Jazz Pharmaceuticals' oncology portfolio includes Erwinase, Asparaginase Erwinia chrysanthemi, among others. This is used to treat acute lymphoblastic leukemia (ALL). Other products in this area include Defitelio and Vyxeos, medications for treating complications in stem cell transplants or acute myeloid leukemia (AML). The neuropathic pain portfolio includes medications such as R-Lipoic Acid, a lipoic acid preparation used to treat diabetic neuropathy. Definitive remnants of burning pain associated with peripheral neuropathy and postherpetic neuralgia are also treated. Jazz Pharmaceuticals also has a product portfolio in the field of hemophilia. The company markets Recombinate, a recombinant human factor VIII preparation for the treatment of hemophilia A, as well as other products for the treatment of hemophilia. In addition to these four core areas, Jazz Pharmaceuticals also has a portfolio of medications used to treat opioid addiction, including the drug Lucemyra. Jazz Pharmaceuticals' business model is based on the development of innovative products for the treatment of rare and complex diseases. The company has a strong presence in the US and European markets and is actively working to expand its presence in other regions through partnerships and acquisitions. Jazz Pharmaceuticals uses a multi-channel strategy to market and distribute its products. The company works closely with doctors, medical professionals, and patient groups to ensure that its medications are made accessible to patients. Overall, Jazz Pharmaceuticals is working to improve the health and well-being of patients suffering from rare and complex diseases. The company is committed to innovation, excellent research and development, and a strong patient focus.

Jazz Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Jazz Pharmaceuticals vai uzņēmums nedod dividendes.

Jazz Pharmaceuticals ISIN ir IE00B4Q5ZN47.

Jazz Pharmaceuticals WKN ir A1JS1K.

Jazz Pharmaceuticals simbols ir JAZZ.

Pēdējo 12 mēnešu laikā Jazz Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Jazz Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Jazz Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Jazz Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Jazz Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Jazz Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Jazz Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 9.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.07.2024..

Pēdējās dividendes izmaksa notika 9.07.2024..

Gadā 2023, Jazz Pharmaceuticals izmaksāja 0 USD dividendes.

Jazz Pharmaceuticals dividendes tiek izmaksātas USD.